Israel to Get Pfizer's Covid Vaccine in January, Netanyahu Says

Grant Boone
November 21, 2020

The results are in the same league as those announced last week by drugmakers Pfizer and BioNTech, which say their jointly-developed vaccine is 90-per-cent effective in preventing COVID-19.

Pfizer said it expected the US FDA vaccine advisory committee to review and discuss the data in a public meeting that will likely be held in December. In those, 90 of them were in the population that did not receive the vaccine, and only five were the only infections that did.

In an interview to CBS on Tuesday, Azar said that Pfizer will be producing 20 million doses of the vaccine every month over the next several months. Europe's STOXX 600 and the U.S S&P 500 futures EScv1 both rose about 0.3% to hit highs for the day.

A key advantage of Moderna's vaccine is that it does not need ultra-cold storage like Pfizer's, making it easier to distribute. Moderna Inc. on Monday its vaccine was 94.5% effective based on the preliminary data.

Moderna expects the vaccine to be stable at normal fridge temperatures of 2 to 8 degrees Celsius (36 to 48°F) for 30 days and it can be stored for up to 6 months at -20C. Of the 95 cases in Moderna's trial, 11 were severe and all 11 occurred among volunteers who got the placebo.

Numerous countries have signed deals with the company already to receive millions of doses of its candidate vaccine.

The contract includes an initial purchase of 225 million doses of the vaccine on behalf of all EU Member States, as well as an option to request up to a further 180 million doses once the shot is proven to be safe and effective against COVID-19. For that we wait for the data.

Macs with Apple M1 Can Now Run Windows Apps Through CrossOver 20
CrossOver is based on the open-source project WINE and emulates Intel Windows binaries via Rosetta 2 on the ARM Mac. "We also installed the beta version of Big Sur 11.1, because we know it has some critical fixes to Rosetta".

"There are many questions still remaining" about the Moderna product and about Pfizer's rival vaccine candidate that has also shown to be very effective in trials, Swaminathan said. Moderna and Johnson & Johnson have said they hope to start testing the vaccine in younger patients soon.

The United States has the world's highest known number of COVID-19 cases and deaths with more than 11 million infections and almost 250,000 deaths.

"It is likely that vaccines that prevent symptomatic disease will reduce the duration and level of infectiousness, and thus reduce transmission, but we don't yet know if this effect will be large enough to make any meaningful difference to the spread of the virus within communities", said Eleanor Riley, professor of immunology and infectious disease at the University of Edinburgh. The only severe adverse events experienced by volunteers were fatigue (3.8%) and headaches (2%) after the second dose.

"These effects are what we would expect with a vaccine that is working and inducing a good immune response", said Peter Openshaw, professor of experimental medicine at Imperial College London.

"The results reported by Pfizer today are very encouraging and add to their announcement from last week", June Raine, chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA), said in a statement, which did not give a precise timeframe for United Kingdom regulatory approval.

Next year, the USA government could have access to more than 1 billion doses just from the two vaccine makers, more than needed for the country's 330 million residents. Brussels also said it was in talks with Moderna about securing doses.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER